KR20210142614A - 암 치료를 위한 이아다뎀스타트 조합물 - Google Patents
암 치료를 위한 이아다뎀스타트 조합물 Download PDFInfo
- Publication number
- KR20210142614A KR20210142614A KR1020217028840A KR20217028840A KR20210142614A KR 20210142614 A KR20210142614 A KR 20210142614A KR 1020217028840 A KR1020217028840 A KR 1020217028840A KR 20217028840 A KR20217028840 A KR 20217028840A KR 20210142614 A KR20210142614 A KR 20210142614A
- Authority
- KR
- South Korea
- Prior art keywords
- combination
- inhibitor
- cancer
- pharmaceutically acceptable
- solvate
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/13—Amines
- A61K31/135—Amines having aromatic rings, e.g. ketamine, nortriptyline
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K2317/00—Immunoglobulins specific features
- C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
- C07K2317/73—Inducing cell death, e.g. apoptosis, necrosis or inhibition of cell proliferation
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Organic Chemistry (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Genetics & Genomics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Biophysics (AREA)
- Biochemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP19382206 | 2019-03-25 | ||
| EP19382206.1 | 2019-03-25 | ||
| PCT/EP2020/058362 WO2020193631A1 (en) | 2019-03-25 | 2020-03-25 | Combinations of iadademstat for cancer therapy |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| KR20210142614A true KR20210142614A (ko) | 2021-11-25 |
Family
ID=66175363
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| KR1020217028840A Ceased KR20210142614A (ko) | 2019-03-25 | 2020-03-25 | 암 치료를 위한 이아다뎀스타트 조합물 |
Country Status (13)
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SG10201913290QA (en) | 2016-03-15 | 2020-03-30 | Oryzon Genomics Sa | Combinations of lsd1 inhibitors for the treatment of hematological malignancies |
| SI3941466T1 (sl) | 2019-03-20 | 2026-04-30 | Oryzon Genomics, S.A. | Vafidemstat za zdravljenje neagresivnih simptomov mejne osebnostne motnje |
Family Cites Families (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US9469597B2 (en) | 2011-10-20 | 2016-10-18 | Oryzon Genomics S.A. | (Hetero)aryl cyclopropylamine compounds as LSD1 inhibitors |
| EP3090998A1 (en) | 2015-05-06 | 2016-11-09 | F. Hoffmann-La Roche AG | Solid forms |
| CN120661674A (zh) | 2016-03-15 | 2025-09-19 | 奥莱松基因组股份有限公司 | 用于治疗实体瘤的lsd1抑制剂的组合 |
| US20190256929A1 (en) * | 2016-11-03 | 2019-08-22 | Oryzon Genomics, S.A. | Pharmacodynamic biomarkers for personalized cancer care using epigenetic modifying agents |
| US11685782B2 (en) * | 2017-10-23 | 2023-06-27 | Children's Medical Center Corporation | Methods of treating cancer using LSD1 inhibitors in combination with immunotherapy |
-
2020
- 2020-03-25 EP EP20712594.9A patent/EP3946295B1/en active Active
- 2020-03-25 BR BR112021016171-6A patent/BR112021016171A2/pt unknown
- 2020-03-25 MX MX2021011610A patent/MX2021011610A/es unknown
- 2020-03-25 WO PCT/EP2020/058362 patent/WO2020193631A1/en not_active Ceased
- 2020-03-25 CN CN202080018266.2A patent/CN113573702A/zh active Pending
- 2020-03-25 PH PH1/2021/552326A patent/PH12021552326A1/en unknown
- 2020-03-25 CA CA3132473A patent/CA3132473A1/en active Pending
- 2020-03-25 CN CN202511368496.2A patent/CN121422229A/zh active Pending
- 2020-03-25 SG SG11202109025XA patent/SG11202109025XA/en unknown
- 2020-03-25 AU AU2020249493A patent/AU2020249493B2/en active Active
- 2020-03-25 KR KR1020217028840A patent/KR20210142614A/ko not_active Ceased
- 2020-03-25 JP JP2021557187A patent/JP7824627B2/ja active Active
- 2020-03-25 US US17/441,758 patent/US20220175698A1/en active Pending
-
2021
- 2021-09-13 IL IL286353A patent/IL286353A/en unknown
-
2026
- 2026-02-13 JP JP2026021790A patent/JP2026077769A/ja not_active Withdrawn
Also Published As
| Publication number | Publication date |
|---|---|
| CN113573702A (zh) | 2021-10-29 |
| JP7824627B2 (ja) | 2026-03-05 |
| SG11202109025XA (en) | 2021-09-29 |
| JP2026077769A (ja) | 2026-05-13 |
| AU2020249493A1 (en) | 2021-09-16 |
| PH12021552326A1 (en) | 2022-06-27 |
| JP2022526525A (ja) | 2022-05-25 |
| EP3946295A1 (en) | 2022-02-09 |
| BR112021016171A2 (pt) | 2021-10-05 |
| CA3132473A1 (en) | 2020-10-01 |
| CN121422229A (zh) | 2026-01-30 |
| US20220175698A1 (en) | 2022-06-09 |
| WO2020193631A1 (en) | 2020-10-01 |
| EP3946295B1 (en) | 2026-08-05 |
| AU2020249493B2 (en) | 2025-08-28 |
| IL286353A (en) | 2021-10-31 |
| MX2021011610A (es) | 2021-10-13 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2012321110B2 (en) | Combination treatment | |
| JP2019517549A5 (cg-RX-API-DMAC10.html) | ||
| RU2006120950A (ru) | Антитело к cd40: препарат и способы | |
| JP2026077769A (ja) | 癌療法のためのイアダデムスタット(iadademstat)の組み合わせ物 | |
| TWI877433B (zh) | 用於治療pik3ca突變癌症的組合療法 | |
| WO2020233602A1 (zh) | 用于联合治疗小细胞肺癌的喹啉衍生物 | |
| CN120826242A (zh) | 抗cd20抗体药物偶联物在制备治疗套细胞淋巴瘤的药物中的用途 | |
| CN118946371A (zh) | 靶向psma的放射性药物和检查点抑制剂的组合疗法 | |
| MXPA04006822A (es) | Combinaciones que comprenden epotilonas y anti-metabolitos. | |
| JP2022547061A5 (cg-RX-API-DMAC10.html) | ||
| RU2833564C2 (ru) | Комбинации иададемстата для лечения рака | |
| TW202308641A (zh) | 用於治療癌症之方法及包含cdk抑制劑之給藥方案 | |
| CN100553634C (zh) | 用于治疗多发性骨髓瘤的埃坡霉素衍生物 | |
| TWI671072B (zh) | 曲氟尿苷(trifluridine)/替匹拉希(tipiracil)鹽酸鹽、抗腫瘤鉑錯合物及免疫檢查點調節子之間的新穎組合 | |
| US20170216339A1 (en) | Anti-tumor agent containing anti-tumor platinum complex, and anti-tumor effect enhancer | |
| US20250302781A1 (en) | Method for pretreating relapsing cancer | |
| RU2837046C1 (ru) | Применение ингибиторов btk при лечении заболеваний | |
| CN105228611B (zh) | 用于治疗或预防头颈癌的pi3激酶抑制剂与紫杉醇的组合 | |
| JP2025516649A5 (cg-RX-API-DMAC10.html) | ||
| CN118436642A (zh) | 干扰肿瘤Treg细胞分化的药物及其应用 | |
| TH2201001953A (th) | การรักษาของโรคตับอักเสบจากแอลกอฮอล์ | |
| US20220378776A1 (en) | Drug combination of quinoline derivative and pd-1 monoclonal antibody | |
| HK40015395A (en) | Combination between trifluridine/tipiracil hydrochloride, an anti-tumor platinum complex, and an immune checkpoint modulator | |
| NZ788180A (en) | Combination therapy with notch and pd-1 or pd-l1 inhibitors |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| PA0105 | International application |
St.27 status event code: A-0-1-A10-A15-nap-PA0105 |
|
| PG1501 | Laying open of application |
St.27 status event code: A-1-1-Q10-Q12-nap-PG1501 |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| P13-X000 | Application amended |
St.27 status event code: A-2-2-P10-P13-nap-X000 |
|
| PA0201 | Request for examination |
St.27 status event code: A-1-2-D10-D11-exm-PA0201 |
|
| D21 | Rejection of application intended |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D21-EXM-PE0902 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0902 | Notice of grounds for rejection |
St.27 status event code: A-1-2-D10-D21-exm-PE0902 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| E13 | Pre-grant limitation requested |
Free format text: ST27 STATUS EVENT CODE: A-2-3-E10-E13-LIM-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| E13-X000 | Pre-grant limitation requested |
St.27 status event code: A-2-3-E10-E13-lim-X000 |
|
| P11 | Amendment of application requested |
Free format text: ST27 STATUS EVENT CODE: A-2-2-P10-P11-NAP-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| P11-X000 | Amendment of application requested |
St.27 status event code: A-2-2-P10-P11-nap-X000 |
|
| B15 | Application refused following examination |
Free format text: ST27 STATUS EVENT CODE: N-2-6-B10-B15-EXM-PE0601 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| PE0601 | Decision on rejection of patent |
St.27 status event code: N-2-6-B10-B15-exm-PE0601 |
|
| T11 | Administrative time limit extension requested |
Free format text: ST27 STATUS EVENT CODE: U-3-3-T10-T11-OTH-X000 (AS PROVIDED BY THE NATIONAL OFFICE) |
|
| T11-X000 | Administrative time limit extension requested |
St.27 status event code: U-3-3-T10-T11-oth-X000 |
|
| T13-X000 | Administrative time limit extension granted |
St.27 status event code: U-3-3-T10-T13-oth-X000 |